Knowledge Center

Article / Mar 08, 2017

Expanding the Commercial Options

Authors:
  • Marcio Temtem
  • Joao Vicente
Source:
Pharma's Almanac, Q1 2017, Mar 8, 2017

Spray drying (SD) and hot-melt extrusion (HME) are commercially proven and accepted amorphous solid dispersion (ASD) technologies for the enhancement of the dissolution and bioavailability of poorly soluble drugs. These approaches are not suitable for all APIs, however. ËÄÉ«AV, in addition to offering non-ASD solutions such as nanomilling and cyclodextrin complexation, is developing an effective coprecipitation technology platform to address this key market need.

Related links

Also in the Knowledge Center

Related Content

·¡±è¾±»å±ð±ôâ„¢

·¡±è¾±»å±ð±ôâ„¢ is an innovative technology with the ability to deliver sustained-release pharmaceuticals via surface erosion resulting in the ability to precisely tune pharmacokinetics to meet the target indication needs.

Page
Read more

Customers

Full transparency for your project anywhere at any time.

Page
Read more

Development

ËÄÉ«AV offers a full range of development services in particle engineering to provides optimal solutions for your drug product.

Page
Read more